學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Guangzhou Kingmed Diagnostics: Post-IPO Transformation
內容大綱
Guangzhou KingMed Diagnostics was the leading third-party independent clinical laboratory in China. On the eve of the Lunar New Year in 2020, the chairman and CEO of Guangzhou KingMed Diagnostics mobilized the whole group to respond to the outbreak of the new coronavirus from Wuhan. With the group's tremendous growth in both business and size since its initial public offering, there were growing concerns about the provision of quality customer service and the group's profitability. While the chairman and CEO was proud to see how swiftly his team had responded to the COVID-19 pandemic, he had many questions about the efficiency of the entire group's resource deployment and the consistency of performance across subsidiaries. Post COVID-19, how should Guangzhou KingMed Diagnostics adjust its transformation strategy?